Brief: Ionis Partner GSK Says FDA Grants Priority Review, Breakthrough Status to Hepatitis B Drug Bepirovirsen
28/04/2026 08:14
April 28 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS PARTNER GSK ANNOUNCES BEPIROVIRSEN ACCEPTED FOR PRIORITY REVIEW AND GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA AS A POTENTIAL FIRST-IN-CLASS MEDICINE FOR CHRONIC HEPATITIS B IONIS PHARMACEUTICALS INC: PDUFA DATE OF OCTOBER 26, 2026 IONIS PHARMACEUTICALS INC: FDA SETS PDUFA TARGET ACTION DATE FOR BEPIROVIRSEN OF OCTOBER 26, 2026 Source text: ID:nBwbgM6WWa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study